Fig. 5
(A) Anatomic sites of cancer types (left panel) and anti-PD-1/PD-L1-related severe cAEs PRR across 27 cancer types (right panel). The anatomic illustration was generated by R package gganatogram v1.130. (B) Spearman correlation between anti-PD-1/PD-L1-related severe cAEs PRR and 39 factors for positive correlation (right) and negative correlation (left). The correlation bar chart was generated by Microsoft Office Excel 365. * indicates significant correlation (FDR < 0.05); PD-L1 mRNA FDR = 2.30 × 10− 3, TCR Diversity FDR = 4.16 × 10− 3, PD-1 mRNA FDR = 7.03 × 10− 3, Lymphocytes FDR = 3.18 × 10− 2, BCR Diversity FDR = 3.18 × 10− 2, Stromal Fraction FDR = 3.18 × 10− 2, Leukocyte Fraction FDR = 3.18 × 10− 2, CD8 + T Cells FDR = 3.44 × 10− 2, Dendritic Cells Resting FDR = 3.44 × 10− 2, T Cells Follicular Helper FDR = 3.44 × 10− 2, Macrophages M1 FDR = 4.02 × 10− 2; (C) Comparison of performance of bivariate models in predicting anti-PD-1/PD-L1-related severe cAEs for all combinations of eleven significantly correlated variables. The heat map of bivariate combination model was generated by Microsoft Office Excel 365. Spearman R (Rs) was calculated between predicted and observed anti-PD-1/PD-L1-related severe cAEs PRR. The shade of the square indicates the Rs, and the size indicates the significance of the log-likelihood ratio test. (D) The combined effect of PD-L1 mRNA and CD8 + T Cells bivariate model (Spearman correlation, Rs = 0.81, FDR = 9.46 × 10− 8). The scatter plot was generated by Microsoft Office Excel 365. The equation of the bivariate model is -0.3164 + 0.6891 × PD-L1 mRNA + 7.5227 × CD8 + T Cells. ACC: adrenocortical carcinoma, AEs: adverse events, BCR Diversity: B cell receptor diversity, BLCA: bladder urothelial carcinoma, BRCA: breast invasive carcinoma, CESC: cervical squamous cell carcinoma and endocervical adenocarcinoma, CHOL: cholangiocarcinoma, COAD: colon adenocarcinoma, ESCA: esophageal carcinoma, FDR: false discovery rate, GBM: glioblastoma multiforme, HNSC: head and neck squamous cell carcinoma, IFN-γ response: interferon-γ response, KICH: Kidney Chromophobe, KIRC: kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LGG: brain lower-grade glioma, LIHC: liver hepatocellular carcinoma, LUAD: lung adenocarcinoma, LUSC: lung squamous cell carcinoma, MESO: mesothelioma, OV: ovarian serous cystadenocarcinoma, PAAD: pancreatic adenocarcinoma, PRAD: prostate adenocarcinoma, PRR: proportional reporting ratio, READ: rectum adenocarcinoma, SARC: sarcoma, SKCM: skin cutaneous melanoma, SNV neoantigens: single-nucleotide variant neoantigens, STAD: stomach adenocarcinoma, TCR Diversity: T cell receptor diversity, TGF-β response: transforming growth factor-β response, THCA: thyroid carcinoma, Th1 Cells: T helper 1 cells, Th2 Cells: T helper 2 cells, Th17 Cells: T helper 17 cells, THYM: Thymoma, TMB: tumour mutation burden, UVM: uveal melanoma.
